Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2020-04-23 | Enrique Conterno, age 53, joined FibroGen, Inc. as our Chief Executive Officer and member of our board of directors in January 2020. ... Due to his extensive history in the pharmaceutical industry with his successful international leadership and oversight of several product launches, we believe Mr. Conterno is exceptionally qualified to serve as our Chief Executive Office and on our board of directors as we prepare for the global commercialization of roxadustat and continue the advancement of our clinical programs. |
| 2022-04-29 | Enrique Conterno, age 55, joined FibroGen as CEO and Director in January 2020... He is not independent... Total compensation in 2021 was $337,072. |
| 2023-04-27 | Enrique Conterno, age 56, joined FibroGen, Inc. as our Chief Executive Officer and member of the Board in January 2020. ... We believe Mr. Conterno is exceptionally qualified to serve as our Chief Executive Officer and on the Board as we commercialize our lead products roxadustat and pamrevlumab and continue the advancement of our clinical programs. ... The following table sets forth information regarding compensation earned by or paid to our non-employee directors during fiscal year 2022: ... James A. Schoeneck, Chairperson $437,839 ... |
Data sourced from SEC filings. Last updated: 2026-02-03